The Manufacturers Life Insurance Company Sells 10,864 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT)

The Manufacturers Life Insurance Company trimmed its holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT) by 30.0% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 25,325 shares of the company’s stock after selling 10,864 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.07% of RAPT Therapeutics worth $77,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in RAPT. Vanguard Group Inc. increased its position in RAPT Therapeutics by 21.2% in the 1st quarter. Vanguard Group Inc. now owns 2,492,850 shares of the company’s stock valued at $22,386,000 after acquiring an additional 436,629 shares in the last quarter. Denali Advisors LLC bought a new stake in shares of RAPT Therapeutics during the first quarter valued at approximately $293,000. Cubist Systematic Strategies LLC grew its stake in shares of RAPT Therapeutics by 826.4% during the second quarter. Cubist Systematic Strategies LLC now owns 295,241 shares of the company’s stock valued at $900,000 after purchasing an additional 263,372 shares during the last quarter. Acadian Asset Management LLC increased its holdings in shares of RAPT Therapeutics by 4,183.3% in the second quarter. Acadian Asset Management LLC now owns 467,182 shares of the company’s stock valued at $1,424,000 after purchasing an additional 456,275 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in RAPT Therapeutics in the 2nd quarter worth approximately $108,000. Institutional investors and hedge funds own 99.09% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on RAPT. UBS Group decreased their price objective on RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating on the stock in a research report on Monday, September 9th. HC Wainwright reaffirmed a “neutral” rating on shares of RAPT Therapeutics in a research note on Tuesday, August 20th. Nine research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $18.17.

RAPT Therapeutics Stock Up 5.9 %

RAPT stock opened at $1.79 on Monday. RAPT Therapeutics, Inc. has a twelve month low of $1.66 and a twelve month high of $27.35. The company has a market cap of $62.47 million, a P/E ratio of -0.57 and a beta of 0.33. The business’s fifty day moving average is $2.02 and its 200-day moving average is $3.79.

RAPT Therapeutics (NASDAQ:RAPT) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.03. Research analysts anticipate that RAPT Therapeutics, Inc. will post -2.73 earnings per share for the current fiscal year.

RAPT Therapeutics Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.